3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Hepatocellular
15
Esophageal Neoplasms
12
Colorectal Neoplasms
9
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Pancreatic Neoplasms
5
Neoplasms
4
Liver Neoplasms
4
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Melanoma
3
Carcinoma, Renal Cell
3
Liver Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Unresectable Biliary Tract Cancer
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Interventions
pembrolizumab
23
Gemcitabine
9
Nivolumab
7
Carboplatin
7
Trastuzumab
6
Early Intervention, Educational
6
avelumab
5
atezolizumab
5
Docetaxel
5
Cisplatin
5
cemiplimab
4
Standard of Care
4
Psychiatric Rehabilitation
4
Paclitaxel
4
Methods
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Fluorouracil
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
pertuzumab
3
fludarabine
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Immunotherapy
×
Gastrointestinal
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled